Doublet Shows Activity in Rare, Aggressive Kidney Cancer

By News Health
8 hours Ago

(MedPage Today) — Bevacizumab (Avastin) combined with erlotinib (Tarceva) showed activity in patients with hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated or sporadic papillary renal cell carcinoma (RCC), a phase II trial suggested…

Source link : https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/116149

Author :

Publish date : 2025-06-18 21:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Dupilumab Linked to Higher Psoriasis Risk in AD

Rapamycin seems to boost longevity as effectively as eating less

Is One Fasting Method Better Than Another?

28 Years Later review: Danny Boyle's long-awaited zombie sequel is a triumph

Study Sheds Light on Links Between Sweetened Drinks and Dementia

Doc's Hidden Camera; Husel's Defamation Suit Tossed; Fugitive Doctor Sentenced